Plasma lipid-lipoprotein-apolipoprotein profile in Chinese patients with diabetes, conorary artery disease, or hypertriglyceridaemia and responses to hypolipidaemic drug therapy.

by Chan Chi Fai.Thesis (M.Phil.)--Chinese University of Hong Kong, 1997.Includes bibliographical references (leaves 119-137).Chapter SECTION 1 --- INTRODUCTIONChapter 1.1 --- Overview on lipids --- p.2Chapter 1.1.1 --- Definition and Classification of Lipids --- p.2Chapter 1.1.2 --- Lipoproteins and Apolipoproteins --- p.4Chapter 1.1.3 --- Outline of Lipoprotein Metabolism --- p.9Chapter 1.1.4 --- LDL Metabolism --- p.12Chapter 1.2 --- Dyslipidaemia and Cardiovascular Disease (CVD) --- p.16Chapter 1.2.1 --- Definition --- p.16Chapter 1.2.2 --- Dyslipidaemia and CAD --- p.16Chapter 1.2.3 --- Dyslipidaemia in Non-Insulin Dependent Diabetes Millitus Patients --- p.18Chapter 1.2.4 --- Claasification of Dyslipidaemia --- p.24Chapter 1.2.5 --- Causes of Hyperlipidaemia --- p.26Chapter 1.3 --- Dyslipidaemia and Atherosclerosis --- p.29Chapter 1.3.1 --- Pathogenesis of Atherosclerosis --- p.29Chapter 1.3.2 --- Mechanism of Atherogenesis --- p.31Chapter 1.3.3 --- Intrinsic Roles of LDL in Atherogenesis --- p.33Chapter (1) --- LDL Oxidizability --- p.33Chapter (2) --- LDL Particle Size Heterogeneity --- p.39Chapter 1.4 --- Management of Dyslipidaemia --- p.42Chapter 1.5 --- Aims of This Study --- p.49Chapter SECTION 2 --- MATERIALS AND METHODSChapter 2.1 --- Materials --- p.52Chapter 2.1.1 --- Patients and Controls --- p.52Chapter 2.1.2 --- Drug Administration Trials --- p.54Chapter 2.1.3 --- Blood Samples --- p.55Chapter 2.1.4 --- Biochemicals --- p.56Chapter 2.1.5 --- Solutions and Buffers --- p.56Chapter 2.1.6 --- Apparatus and Equipment --- p.60Chapter 2.2 --- Methods --- p.62Chapter 2.2.1 --- General Clinical Biochemistry Tests --- p.62Chapter 2.2.2 --- Apolipoprotein Assays --- p.62Chapter 2.2.3 --- Ultracentrifugation of LDL Fraction --- p.63Chapter 2.2.4 --- De-Salting of LDL Fraction --- p.64Chapter 2.2.5 --- Qualitative Determination of LDL-Cholesterol and Protein Fractions --- p.64Chapter 2.2.6 --- In Vitro Assessment of LDL Oxidizability --- p.65Chapter 2.2.7 --- Electrophoretic Gel Pattern of LDL Fraction During In Vitro Oxidizability --- p.65Chapter 2.2.8 --- Study of LDL Particle Size --- p.66Chapter 2.2.9 --- Statistical Analysis --- p.67Chapter SECTION 3 --- RESULTSChapter 3.1 --- Quantitative Determination and Standardization of LDL Fractions --- p.69Chapter 3.2 --- In Vitro Assessment of LDL Oxidizability --- p.72Chapter 3.3 --- Electrophoretic Patterns of LDL during In Vitro Oxidizability --- p.72Chapter 3.4 --- LDL Sizing --- p.73Chapter 3.5 --- "Correlations of Triglycerides Concentration, LDL Particle Size and Oxidizability" --- p.76Chapter 3.6 --- Diabetes Millitus --- p.83Chapter 3.6.1 --- NIDDM Patients & Controls --- p.83Chapter 3.6.2 --- Effect of Drug Treatment on Serum Lipid-Lipoprotein- Apolipoprotein Profile --- p.86Chapter 3.7 --- Hypertriglyceridaemic Patients --- p.90Chapter 3.7.1 --- Patients & Controls --- p.90Chapter 3.7.2 --- Bezafibrate Treatment --- p.91Chapter 3.8 --- CAD Patients --- p.97Chapter 3.8.1 --- CAD Patients & Controls --- p.97Chapter SECTION 4 --- DISCUSSIONChapter 4.1 --- Patients and Controls --- p.101Chapter 4.2 --- Ultracentrifugation of LDL Fractions --- p.102Chapter 4.3 --- In Vitro LDL Oxidizability --- p.103Chapter 4.4 --- "Association of TG, LDL Oxidizability and Particle Size" --- p.105Chapter 4.5 --- LDL Sizing --- p.106Chapter 4.6 --- Comparsion of Patients and Controls in Lipid-Lipoprotein- Apolipoprotein Profiles --- p.107Chapter 4.7 --- The Effect of Lovastatin and Acipimox on NIDDM Patients --- p.111Chapter 4.8 --- The Effect of Bezafibrate on Hypertriglyceridaemic Patients --- p.114Chapter SECTION 5 --- CONCLUSION --- p.116References --- p.119Appendices --- p.13